Last updated: May 25, 2026
Chloroprocaine Hydrochloride Suppliers (API, Drug Product, and Contract Manufacturing)
Suppliers for chloroprocaine hydrochloride span (1) active pharmaceutical ingredient (API) manufacturers and (2) drug-product (injectable anesthetic) manufacturers, plus (3) contract manufacturing organizations (CMOs) that can supply sterile injectables and related packaging. This supply map is jurisdiction- and form-dependent (plain injectable vs preservative-free, strengths, vial vs ampule).
What companies supply chloroprocaine hydrochloride API for generic injectables?
Chloroprocaine hydrochloride is commonly supplied as an API for sterile injectable anesthetic products in the US and abroad. The supply chain for generic injectables is typically segmented into:
- API suppliers (chloroprocaine HCl synthesis and isolation)
- sterile fill-finish CMOs (aseptic filling, lyophilization where applicable, sterility assurance)
- drug-product brand/generic marketers (ANDA holders and label owners)
API supplier list
- Sichuan Zhengda Tianqing Pharmaceutical Co., Ltd. (chloroprocaine hydrochloride listed for pharmaceutical production; China)
- Hangzhou Minsheng Pharmaceutical Co., Ltd. (chloroprocaine hydrochloride; China)
- Shanxi Huayu Pharmaceutical Co., Ltd. (chloroprocaine hydrochloride; China)
- Zhejiang Wansheng Pharmaceutical Co., Ltd. (chloroprocaine hydrochloride; China)
- Jiangsu Wanlong Pharmaceutical Co., Ltd. (chloroprocaine hydrochloride; China)
Which companies manufacture chloroprocaine hydrochloride injectable drug products?
Chloroprocaine hydrochloride is marketed as an injectable local anesthetic. Manufacturers generally include US and international sterile injectable producers, often as ANDA holders for generic strength-and-presentation products.
Drug-product (injectable) manufacturers and labelers (US-generic ecosystem)
- Hikma Pharmaceuticals (injectable local anesthetic product portfolio in the US market; chloroprocaine products appear as authorized generics/ANDAs depending on strength and presentation)
- B. Braun Medical Inc. (sterile injectable capability and anesthetic product lines; chloroprocaine formulations appear in distribution under various market labels)
- Fresenius Kabi (US sterile injectable manufacturer; local anesthetic injectable portfolio depends on specific chloroprocaine presentation)
How do CMOs support chloroprocaine hydrochloride sterile supply?
For chloroprocaine hydrochloride injectables, supply continuity depends on fill-finish capacity and sterility assurance. CMOs that support sterile injectable manufacturing typically offer:
- aseptic processing or terminal sterilization workflows (depending on formulation)
- container closure systems for vials/ampules
- cGMP release testing (sterility, endotoxin, particulate, assay)
CMT/CMO category examples used in sterile injectables
- Boehringer Ingelheim / Roche CMO networks (regional sterile operations, used by multiple sterile generic and branded injectables)
- Sandoz / Novartis sterile manufacturing networks (sterile drug-product operations in Europe/US supporting generics)
- Lonza sterile fill-finish footprint (CMO capacity for sterile injectables; dependent on specific contract award)
Which suppliers are most relevant by region (US, EU, India, China)?
China and India typically lead API supply for chloroprocaine hydrochloride used in generic injectables.
EU and US sourcing shifts toward certified sterile manufacturers and ANDA holders with local fill-finish or imported drug product.
What presentations and strengths change the supplier list?
Supplier availability varies by:
- strength (eg, 1% vs 2% solutions)
- container type (vials vs ampules)
- preservative status (preservative-containing vs preservative-free where offered)
- packaging and distribution (single-dose vs multi-dose where applicable)
How to shortlist chloroprocaine hydrochloride suppliers for licensing or procurement?
A defensible short list is built on:
- regulatory footprint (DMFs for API or approved ANDA/label history for drug product)
- sterile manufacturing certification (EU GMP / US FDA inspections for relevant sites)
- supply continuity evidence (batch release frequency and documented supply history)
- ability to support specific container-closure requirements and labeling needs
- quality system maturity (deviation history, CAPA turnaround time, sterility assurance controls)
Key Takeaways
- Chloroprocaine hydrochloride supply is split between API makers (often China-based) and sterile injectable manufacturers/labelers (US and EU).
- For procurement or licensing, the most reliable supplier screen is not “API availability” alone, but DMF/ANDA/regulatory history paired with sterile fill-finish capability for the exact presentation.
- Supplier lists must be matched to formulation specifics: strength, container type, and preservative status.
FAQs
- Do chloroprocaine hydrochloride API suppliers support US FDA DMF filings?
- Which sterile injectables CMOs handle local anesthetic workflows for chloroprocaine HCl?
- What container types (vials vs ampules) are most common for chloroprocaine hydrochloride generics?
- How do preservative status and formulation affect supplier qualification for chloroprocaine HCl injections?
- What are the most common batch-release bottlenecks for chloroprocaine hydrochloride sterile products?
References
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
- FDA. Drug Master Files (DMF) listings and submission information (public index). U.S. Food and Drug Administration.
- EMA. European Medicines Agency public documentation and GMP inspection summaries. European Medicines Agency.
- Company websites and public corporate fact sheets for sterile manufacturing and APIs (as available in public domains).
